Events & Presentations

Presentations

a scientist with vials being tested

Earnings Presentations

Oct 30, 2024
Q3 2024 Biogen Earnings Presentation
Aug 01, 2024
Q2 2024 Biogen Earnings Presentation
Apr 24, 2024
Q1 2024 Biogen Earnings Presentation
Feb 13, 2024
Q4 and Full Year 2023 Biogen Earnings Presentation
Nov 08, 2023
Q3 2023 Biogen Earnings Presentation

Investor R&D Day 2021

Sep 21, 2021
Biogen 2021 Investor R&D Day
Sep 21, 2021
Biogen Digital Health
Sep 21, 2021
Advancements in Research
Sep 21, 2021
Biogen Gene Therapy
Sep 21, 2021
Alzheimer’s Disease Research Portfolio
Sep 21, 2021
Biomarkers
Sep 21, 2021
Biotherapeutics and Medicinal Sciences at Biogen
Sep 21, 2021
Human Genetics
Sep 21, 2021
Movement Disorders at Biogen
Sep 21, 2021
MS Portfolio

Conference and Other Investor Presentations

Jul 28, 2023
Proposed Acquisition of Reata Pharmaceuticals, Inc.
Dec 06, 2022
Biogen and Sage Zuranolone Webcast Presentation
Jan 13, 2022
Biogen Analyst Q&A Call
Jun 08, 2021
Biogen ADUHELM Launch
Oct 22, 2019
Aducanumab Update Presentation
Jun 05, 2019
Biogen ALS & R&D Portfolio Webcast Presentation
Mar 04, 2019
Biogen Planned Acquisition of Nightstar Therapeutics
Dec 12, 2018
Biogen MS & R&D Webcast Presentation
Jun 28, 2018
Biogen on R&D Progress Targeting Stroke

Medical and Scientific Conference Presentations

Mar 15, 2022
Aducanumab Phase 3 Studies: Exposure-Response Analysis Evaluating the Relationship Between Amyloid Removal and Slowing of Clinical Decline on CDR-SB Scores at AD/PD
Nov 11, 2021
Dose and time dependent changes in plasma ptau181 in patients treated with aducanumab in the ENGAGE and EMERGE trials at CTAD
Nov 09, 2021
Baseline EMBARK data from EMERGE, ENGAGE, and PRIME participants in the EMBARK re-dosing study at CTAD
Oct 17, 2021
Results from the Phase 3 VALOR study and its open-label extension at ANA 2021 View Presentation
Jul 29, 2021
ICARE AD-US: Design of a Prospective, Single-arm, Multicenter, Noninterventional Real-world Study of Aducanumab in United States
Jul 26, 2021
Results of the First-in-Human, Randomized, Double-Blind, Placebo-Controlled Phase 1b Study of Lumbar Intrathecal Bolus Administrations of Antisense Oligonucleotide (ISIS 814907; BIIB080) Targeting Tau mRNA in Patients with Mild Alzheimer’s Disease
Jul 26, 2021
Subgroup Analyses of the Amyloid PET Substudies from EMERGE and ENGAGE, Phase 3 Clinical Trials Evaluating Aducanumab in Patients with Early Alzheimer’s Disease
Jul 26, 2021
Item-level Analysis of Clinical Measures in Patients with Early Symptomatic Alzheimer’s Disease Following Treatment with High-Dose Aducanumab in the Phase 3 Study EMERGE
Jul 26, 2021
Reduction in Biomarkers of Alzheimer’s Disease Pathophysiology Following Treatment with Aducanumab Were Associated with Slowing Clinical Decline
Jul 26, 2021
Considerations for the Real-World Management of ARIA from the Aducanumab Phase 3 Studies EMERGE and ENGAGE

Annual Stockholder Presentation

June 15, 2022
Biogen Annual Stockholder Presentation 2022

Hemophilia Spin-off Presentations

January 6, 2017
Bioverativ (BIVV) Analyst Day Presentation
May 3, 2016
Hemophilia Spin-off Presentation
Stockholder Communications icon

Stockholder Communications

E-mail Alerts icon

E-mail Alerts

FAQs icon

FAQs

Learn more about our Events & Presentations